MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Neuroprotective agents"

  • 2017 International Congress

    Neuroprotective Potency of Tetrahydroisoquinoline a Novel Ayurveda Molecule in Experimental Parkinson’s Disease

    R. Banerjee, D. Nthenge-Ngumbau, R. Singh, P. Jaisankar, K. Mohanakumar, S. Biswas (Kolkata, India)

    Objective: Tetrahydroisoquinoline (TIQ) an identified alkaloid from ancient Indian ‘Ayurveda’ medicine for Parkinson’s disease (PD) was tested for neuroprotection in a cellular system and a…
  • 2017 International Congress

    Multi-modal retention in a phase III clinical trial in early Parkinson disease (STEADY-PD III)

    B. Greco, T. Simuni, J. Denmark, S. Henderson, J. Lowell, S. Sharma, C. Tarolli, D. Young, K. Biglan (Rochester, NY, USA)

    Objective: To evaluate novel retention strategies in an ongoing phase 3 clinical trial in individuals with Parkinson disease (PD) Background: Adequate participant retention is a…
  • 2017 International Congress

    CB2R agonist AM1241 reverses the development of MPTP-induced PD and activates the regeneration of DA neurons

    R. Zhu (Shanghai, China)

    Objective: A promising and potential direction to treat PD is to develop new non-dopaminergic drugs without producing dyskinesia, as well as arresting and even reversing…
  • 2017 International Congress

    AAV-mediated over-expression of VEGF-B in PINK1 gene knockout rats increases striatal dopamine content

    T. Falk, M. Bartlett, D. Muller, B. Silashki, D. Farrell, K. Parent, M. Heien, S. Sherman (Tucson, AZ, USA)

    Objective: To evaluate overexpression of the neuroprotective vascular endothelial growth factor B (VEGF-B) in a genetic Parkinson’s disease (PD) model. Background: We have shown in…
  • 2017 International Congress

    Piperine potentiate the neuroprotective effect of quercetin against MPTP induced neurotoxicity in rats

    S. Singh, P. Kumar (Moga, India)

    Objective: (1) Quercetin is well tolerated bioflavonoid used as supplement for various disorders but problem is its low oral bioavailability and (2) Piperine is combined…
  • 2017 International Congress

    Protective effect of Myristicin against neurodegeneration in a 6-hydroxydopamine induced model of Parkinson’s disease in rats

    A. Morad Ganjeh (Karaj, Islamic Republic of Iran)

    Objective: This study examined the effect of pretreatment with Myristicin on the severity of 6-hydroxydopamine-induced Parkinsonism in Wistar rats in order to find out whether…
  • 2017 International Congress

    Piper betle L. Attenuates 6-OHDA Induced Apoptosis in SH-SY5Y Cells and Neuronal Injury in Caenorhabditis elegans Parkinson’s Model

    G. Shanmugam, A. Mohankumar, P. Sundararaj (Coimbatore, India)

    Objective: To explore the anti-apoptotic effects of Piper bitle leaf extract (PLE) on 6-OHDA induced cellular injury in human neuroblastoma cell SH-SY5Y. To analyse the neuroprotective…
  • 2017 International Congress

    Role of Apocyanin in modulating glial cell functions and associated inflammatory response in Lipopolysaccharide induced Parkinson’s disease model.

    N. Sharma, B. Nehru (Chandigarh, India)

    Objective: To explore the effect of apocyanin on glia mediated inflammatory response and α-synuclein aggregation in single intranigral LPS induced PD model Background: Converging lines…
  • 2017 International Congress

    MANF protects dopamine neurons and locomotion defect from Neurotoxin/Human alpha-synuclein-induced progressive Parkinson’s disease models in C.elegans.

    Z. Zhang (Shanghai, China)

    Objective: To study whether Mesencephalic astrocyte-derived neurotrophic factor (MANF) has beneficial effects in parkinson disease and its intracellular mechanisms.  Background: The distinguishing feature of Parkinson’s…
  • 2017 International Congress

    Neuroprotective effects of antidepressant mirtazapine against dopaminergic neurodegeneration in cultured cells and in parkinsonian mice possibly by targeting astrocytes

    M. Asanuma, I. Miyazaki, R. Kikuoka, S. Murakami, N. Isooka, Y. Kitamura (Okayama, Japan)

    Objective: In this study, we examined neuroprotective effects of mirtazapine and involvement of astrocytes in the effects using primary cultured cells and parkinsonian mice. Background:…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • #24475 (not found)
  • Preclinical characterization of UCB0022, an oral, brain penetrant, selective, clinical-stage positive allosteric modulator of the dopamine 1 receptor (D1 PAM)
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley